NO20062090L - Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid - Google Patents

Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Info

Publication number: NO20062090L
Authority: NO; Norway
Prior art keywords: polymorphic form; benzamide; difluoro; dihydroxy; propoxy
Prior art date: 2003-10-21

Application number

NO20062090A

Other languages

English (en)

Norwegian (no)

Inventor

Dainius Mackikenas

Thomas Nanninga

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-21

Filing date

2006-05-09

Publication date

2006-07-12

2006-05-09 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-07-12 Publication of NO20062090L publication Critical patent/NO20062090L/no

Links

SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 title abstract 2
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Cardiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)

NO20062090A 2003-10-21 2006-05-09 Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid NO20062090L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51298003P	2003-10-21	2003-10-21
PCT/IB2004/003309 WO2005040098A1 (en)	2003-10-21	2004-10-11	Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Publications (1)

Publication Number	Publication Date
NO20062090L true NO20062090L (no)	2006-07-12

Family

ID=34520067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062090A NO20062090L (no)	2003-10-21	2006-05-09	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Country Status (18)

Country	Link
US (1)	US7060856B2 (pt)
EP (1)	EP1682495A1 (pt)
JP (1)	JP2007509125A (pt)
KR (1)	KR101013932B1 (pt)
CN (1)	CN100594212C (pt)
AR (1)	AR046124A1 (pt)
AU (1)	AU2004283148A1 (pt)
BR (1)	BRPI0415710A (pt)
CA (1)	CA2542210A1 (pt)
CO (1)	CO5690569A2 (pt)
IL (1)	IL174367A0 (pt)
MX (1)	MXPA06004363A (pt)
NO (1)	NO20062090L (pt)
NZ (1)	NZ546011A (pt)
RU (1)	RU2352558C2 (pt)
TW (1)	TW200524584A (pt)
WO (1)	WO2005040098A1 (pt)
ZA (1)	ZA200602250B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002092094A1 (en) *	2001-03-27	2002-11-21	Sumitomo Pharmaceuticals Co., Ltd.	Crystalline isoxazole derivative and medical preparation thereof
WO2006061712A2 (en) *	2004-12-10	2006-06-15	Pfizer Inc.	Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) *	2005-06-14	2006-12-21	Warner-Lambert Company Llc	Methods of preparing mek inhibitor
WO2007042885A2 (en) *	2005-10-07	2007-04-19	Pfizer Products Inc.	Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
CA2737461A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care, Inc.	Solute concentration measurement device and related methods
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US8573027B2 (en)	2009-02-27	2013-11-05	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US8926561B2 (en)	2009-07-30	2015-01-06	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
SG178986A1 (en)	2009-09-08	2012-04-27	Hoffmann La Roche	4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PH12012501361A1 (en)	2009-12-31	2012-10-22	Centro Nac De Investigaciones Oncologicas Cnio	Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en)	2010-01-22	2015-07-07	Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii	Inhibitors of PI3 kinase
PH12012501662A1 (en)	2010-02-18	2012-10-22	Centro Nac De Investigaciones Oncologicas Cnio	Triazolo [4,5 - b] pyridin derivatives
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2012052745A1 (en)	2010-10-21	2012-04-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en)	2011-01-18	2012-07-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CN102649773A (zh) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
WO2012135781A1 (en)	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
RU2013148817A (ru) *	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений-ингибиторов акт и мек и способы их применения
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
PL2710018T3 (pl)	2011-05-19	2022-04-04	Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Związki makrocykliczne jako inhibitory kinaz białkowych
WO2013005057A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	New compounds
WO2013005041A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncologicas (Cnio)	Tricyclic compounds for use as kinase inhibitors
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103570594A (zh) *	2012-08-01	2014-02-12	苏州迈泰生物技术有限公司	二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
CA3207271A1 (en) *	2021-02-17	2022-08-25	Kristin Patterson	Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en)	2021-02-17	2023-02-07	Springworks Therapeutics, Inc.	Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en)	2021-02-17	2021-08-10	Springworks Therapeutics, Inc.	Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
IL304974A (en) *	2021-02-17	2023-10-01	Warner Lambert Co	Preparations of mainly pure configuration IV of N-((R)-3,2-dihydroxypropoxy)-4,3-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and their uses
MX2023009560A (es) *	2021-02-17	2023-10-25	Springworks Therapeutics Inc	Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
US11066358B1 (en)	2021-02-17	2021-07-20	Warner-Lambert Company Llc	Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
CA3254428A1 (en)	2022-03-17	2023-09-21	SpringWorks Therapeutics Inc.	TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB
EP4493169A4 (en) *	2022-03-17	2026-03-04	Springworks Therapeutics Inc	Fluorinated phenylamine compounds and pharmaceutical compositions
US20250282715A1 (en)	2022-05-17	2025-09-11	Assia Chemical Industries Ltd.	Solid state forms of mirdametinib and process for preparation thereof
KR20250160454A (ko)	2023-03-16	2025-11-13	스프링웍스 테라퓨틱스, 인크.	미르다메티닙의 투여 형태

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA702961B (en) *	1969-05-15	1971-01-27	Nippon Soda Co	Benzohydroxamates,preparations and uses thereof
US5155110A (en) *	1987-10-27	1992-10-13	Warner-Lambert Company	Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
AU5610398A (en)	1997-02-28	1998-09-18	Warner-Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
BR9810385A (pt)	1997-07-01	2000-09-05	Warner Lambert Co	Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek
NZ501276A (en)	1997-07-01	2000-10-27	Warner Lambert Co	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
GB9726851D0 (en) *	1997-12-19	1998-02-18	Zeneca Ltd	Human signal transduction serine/threonine kinase
EP1043989A4 (en)	1998-01-06	2002-09-25	Gen Hospital Corp	USE OF MEK1 INHIBITORS AS A PROTECTIVE AGAINST CHEMICAL DAMAGE
AU1549700A (en)	1998-12-04	2000-06-26	Neurosearch A/S	Ion channel modulating agents
AU2180500A (en)	1998-12-15	2000-07-03	Warner-Lambert Company	Use of a mek inhibitor for preventing transplant rejection
EP1143957A3 (en)	1998-12-16	2002-02-27	Warner-Lambert Company	Treatment of arthritis with mek inhibitors
AP2001002175A0 (en)	1998-12-22	2001-06-21	Warner Lambert Co	Combination chemotherapy.
EP1140062B1 (en)	1999-01-07	2005-04-06	Warner-Lambert Company LLC	Treatment of asthma with mek inhibitors
WO2000040237A1 (en)	1999-01-07	2000-07-13	Warner-Lambert Company	Antiviral method using mek inhibitors
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
CA2349180A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	Anthranilic acid derivatives
JP2001055376A (ja)	1999-01-13	2001-02-27	Warner Lambert Co	ジアリールアミン
IL144214A0 (en) *	1999-01-13	2002-05-23	Warner Lambert Co	Benzoheterocycles and their use as mek inhibitors
CA2349832A1 (en)	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
DE69926914T2 (de)	1999-01-13	2006-06-29	Warner-Lambert Co. Llc	1-heterozyklus-substituierte diarylaminen
ATE311363T1 (de)	1999-01-13	2005-12-15	Warner Lambert Co	Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
KR20020012315A (ko)	1999-07-16	2002-02-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
HUP0202381A3 (en)	1999-07-16	2004-12-28	Warner Lambert Co	Method for treating chronic pain using mek inhibitors
ES2208364T3 (es)	1999-07-16	2004-06-16	Warner-Lambert Company Llc	Procedimiento para tratar dolor cronico usando inhibidores de mek.
EP1246823A1 (en)	1999-12-28	2002-10-09	Pharmacopeia, Inc.	Pyrimidine and triazine kinase inhibitors
MXPA02008103A (es)	2000-03-15	2002-11-29	Warner Lambert Co	Diarilaminas sustituidas con 5-amida como inhibidores mek.
DE10017480A1 (de) *	2000-04-07	2001-10-11	Transmit Technologietransfer	Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP3811775B2 (ja) *	2000-07-19	2006-08-23	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
SK2072003A3 (en)	2000-08-25	2004-01-08	Warner Lambert Co	Process for making N-aryl-anthranilic acids and their derivatives
HUP0302928A3 (en) *	2000-09-08	2005-03-29	Ono Pharmaceutical Co	Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenyl-carbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient
EP1420778B1 (en)	2001-03-06	2006-11-22	Dorian Bevec	Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
AU2002255852B2 (en)	2001-03-22	2006-11-09	Van Andel Research Institute	Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) *	2001-05-09	2002-11-10	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002348791A1 (en) *	2001-12-21	2003-07-09	Warner-Lambert Company Llc	Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
DOP2003000556A (es)	2002-01-23	2003-10-31	Warner Lambert Co	Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
CA2473545A1 (en)	2002-01-23	2003-07-31	Warner-Lambert Company Llc	N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
MXPA05003431A (es) *	2002-11-15	2005-07-05	Warner Lambert Co	Quimioterapia de combinacion.

2004
- 2004-10-11 NZ NZ546011A patent/NZ546011A/en unknown
- 2004-10-11 KR KR1020067007613A patent/KR101013932B1/ko not_active Expired - Fee Related
- 2004-10-11 BR BRPI0415710-9A patent/BRPI0415710A/pt not_active IP Right Cessation
- 2004-10-11 EP EP04769603A patent/EP1682495A1/en not_active Withdrawn
- 2004-10-11 JP JP2006536192A patent/JP2007509125A/ja active Pending
- 2004-10-11 WO PCT/IB2004/003309 patent/WO2005040098A1/en not_active Ceased
- 2004-10-11 CN CN200480030534A patent/CN100594212C/zh not_active Expired - Fee Related
- 2004-10-11 AU AU2004283148A patent/AU2004283148A1/en not_active Abandoned
- 2004-10-11 RU RU2006113437/04A patent/RU2352558C2/ru not_active IP Right Cessation
- 2004-10-11 MX MXPA06004363A patent/MXPA06004363A/es unknown
- 2004-10-11 CA CA002542210A patent/CA2542210A1/en not_active Abandoned
- 2004-10-19 AR ARP040103782A patent/AR046124A1/es not_active Application Discontinuation
- 2004-10-20 US US10/969,681 patent/US7060856B2/en not_active Expired - Fee Related
- 2004-10-20 TW TW093131810A patent/TW200524584A/zh unknown
2006
- 2006-03-16 IL IL174367A patent/IL174367A0/en unknown
- 2006-03-17 ZA ZA200602250A patent/ZA200602250B/en unknown
- 2006-04-20 CO CO06037639A patent/CO5690569A2/es not_active Application Discontinuation
- 2006-05-09 NO NO20062090A patent/NO20062090L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2006113437A (ru)	2006-08-27
TW200524584A (en)	2005-08-01
KR20060080230A (ko)	2006-07-07
KR101013932B1 (ko)	2011-02-14
RU2352558C2 (ru)	2009-04-20
MXPA06004363A (es)	2006-06-14
AR046124A1 (es)	2005-11-23
CN100594212C (zh)	2010-03-17
CO5690569A2 (es)	2006-10-31
CA2542210A1 (en)	2005-05-06
IL174367A0 (en)	2006-08-01
HK1093483A1 (en)	2007-03-02
BRPI0415710A (pt)	2006-12-19
ZA200602250B (en)	2007-05-30
JP2007509125A (ja)	2007-04-12
AU2004283148A1 (en)	2005-05-06
NZ546011A (en)	2009-09-25
CN1867543A (zh)	2006-11-22
US7060856B2 (en)	2006-06-13
EP1682495A1 (en)	2006-07-26
WO2005040098A1 (en)	2005-05-06
US20050085550A1 (en)	2005-04-21

Legal Events

Date	Code	Title	Description
2009-05-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20062090L (no)	2006-07-12	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid
NO20045065L (no)	2005-01-07	Nytt formatsalt av o-desmetyl-venlafaxin
EA200300873A1 (ru)	2003-12-25	Новая соль сукцинат o-десметилвенлафаксина
DK1414428T3 (da)	2009-08-31	Histondeacetylaseenzym-inhiberende derivater af hydroxamsyre som hidtil ukendt cytokinsyntese-inhiberende anti-inflammatoriske lægemidler
NO20053846L (no)	2005-08-16	Fremgangsmate for a modifisere legemiddel-krystalldannelse
NO20053088L (no)	2005-06-23	Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
DK1446380T3 (da)	2010-01-04	Formoteroltartrafremgangsmåde og polymorf
BRPI0410959A (pt)	2006-07-04	composição farmacêutica contendo inibidor de histona desacetilase
NO20054018L (no)	2005-08-30	Intranasal formulering av rotigotin
IL192233A0 (en)	2008-12-29	Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a subsituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing them
HUP0402560A2 (hu)	2005-04-28	N-(Adamantil-metil)-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
NO20040314L (no)	2004-03-25	Nye forbindelser
NO20030304D0 (no)	2003-01-20	Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasöytisk formulering
DE60302157D1 (de)	2005-12-08	Opioidrezeptorantagonisten
BR0115501A (pt)	2003-10-21	Processo quìmico e novos intermediários
ATE325135T1 (de)	2006-06-15	2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
WO2004098516A3 (en)	2005-07-07	Cyclic derivatives as modulators of chemokine receptor activity
NO20052698L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
ATE547400T1 (de)	2012-03-15	N-alkylierte diaminopropanderivate als modulatoren der chemokinrezeptoraktivität
NO20063308L (no)	2006-09-12	Kombinasjon av flupirtin og tramadol
BRPI0412459A (pt)	2006-10-17	composto tendo ação anti-hcv e seu método de produção
DK1594460T3 (da)	2008-07-28	Tramadol-formuleringer med forlænget frigivelse og 24 timers effektivitet
MX2023009559A (es)	2023-10-25	Formulaciones dispersables de n-((r)-2,3-dihidroxipropoxi)-3,4-dif luoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
NO995676L (no)	1999-11-19	Isoftalamid derivat som gul polymorf
EA200601086A1 (ru)	2006-12-29	Новый способ синтеза периндоприла и его фармацевтически приемлемых солей